

EFFECT OF SAW PALMETTO EXTRACT ON AUTONOMIC RECEPTORS IN THE LOWER URINARY TRACT OF RAT

Hypothesis / aims of study

Phytotherapeutic agents, including Saw palmetto extract (SPE), are popular in many European countries as herbal remedies represent up to 80% of all drugs prescribed for benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). However, the mechanism of pharmacological action of SPE is not fully elucidated. Animal experiments with SPE have demonstrated antiandrogen activity and inhibition of 5 α -reductase, the enzyme that converts testosterone to its active metabolite, dihydrotestosterone [1]. Recently, we have demonstrated that SPE alleviates significantly urodynamic symptoms in acetic acid-induced hyperactive rat bladders by increasing bladder capacity and subsequently prolonging the micturition interval. α_1 -Adrenoceptor antagonists and muscarinic cholinergic receptor antagonists are commonly used in the treatment of men with voiding symptoms (urinary obstruction, pollakiuria and urinary incontinence) secondary to BPH. Thus, such improvement of voiding symptoms by SPE might be expected to result from its significant antagonism of autonomic receptors in the lower urinary tract because SPE contains many constituents. In fact, Goepel et al. [2] have shown that SPE has α_1 -adrenoceptor inhibitory property. Thus, we examined the binding activities of SPE and its crude fractions to several receptors (α_1 -adrenoceptors, muscarinic cholinergic receptors, 1,4-dihydropyridine calcium channel antagonist receptors and P2X receptors) in the prostate and bladder of rats.

Study design, materials and methods

The rat bladder and prostate were excised and the homogenates were used for the radioligand binding assays of each receptor. Muscarinic cholinergic receptors, 1,4-dihydropyridine calcium channel antagonist receptors and P2X receptors in the rat bladder and α_1 -adrenoceptors in the prostate were measured by radioligand binding assays of [³H]N-methylscopolamine (NMS), (+)-[³H]PN 200-110, [³H] α_1 -MeATP and [³H]prazosin, respectively.

Results

Relatively low concentrations (10-1000 μ g/mL) of SPE inhibited specific binding of [³H]NMS and (+)-[³H]PN 200-110 (rat bladder) and [³H]prazosin (prostate) in a concentration dependent manner, and their IC₅₀ values were 40.0, 93.7 and 169 μ g/mL, respectively. Furthermore, SPE (0.1-1000 μ g/mL) did not inhibit specific binding of [³H] α_1 -MeATP in the rat bladder. n-Hexane fraction and diethyl ether fraction of SPE (10-500 μ g/mL) inhibited specific binding of [³H]NMS and (+)-[³H]PN 200-110 in the rat bladder and [³H]prazosin in the prostate in a concentration dependent manner. The IC₅₀ values of n-hexane fraction and diethyl ether fraction of SPE were 67.9 and 57.7 μ g/mL for [³H]NMS, 31.0 and 37.5 μ g/mL for (+)-[³H]PN 200-110, 195 and 208 μ g/mL for [³H]prazosin, respectively. SPE ([³H]NMS: 50 μ g/mL, (+)-[³H]PN 200-110: 100 μ g/mL, [³H]prazosin: 150 μ g/mL) brought about a significant (30.2-66.6%) decrease of maximal number of binding sites for [³H]NMS and (+)-[³H]PN 200-110 in the rat bladder and for [³H]prazosin in the prostate, respectively.

Interpretation of results

These data suggest that SPE exerts significant binding activities of autonomic and calcium channel antagonist receptors in the prostate and bladder, targeting sites of drugs used clinically in the treatment of BPH and LUTS. Moreover, the n-hexane and diethyl ether fractions of SPE may contain active constituents for these receptors.

Concluding message

The present study has first shown that SPE may act as relatively potent agonists and/or antagonists of muscarinic cholinergic receptors, α_1 -adrenoceptors and 1,4-dihydropyridine calcium channel antagonist receptors in the lower urinary tract.

References:

- [1] Palin, M.F., et al.: Inhibitory effects of *Serenoa repens* on the kinetic of pig prostatic microsomal 5 α -reductase activity. *Endocrine*. 9:65-69, 1998.
- [2] Goepel, M., et al.: Saw palmetto extracts potently and noncompetitively inhibit human α_1 -adrenoceptors in vitro. *The Prostate*, 38:208-215, 1999.